Lupin’s US subsidiary, Lupin Pharmaceuticals Inc. has launched its Metformin HCI ER Tablets, 500 mg and 1000 mg to market a generic equivalent of Santarus Inc.’s Glumetza HCI ER Tablets, 500 mg and 1000 mg.
Lupin’s Metformin HCI ER Tablets, 500 mg and 1000 mg are the AB-rated generic equivalent of Santarus Inc.’s Glumetza HCI ER Tablets, 500 mg and 1000 mg strengths. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus.
Lupin is eligible for 180 days of generic drug exclusivity for its Metformin HCI ER Tablets, 500 mg and 1000 mg. Glumetza HCI ER Tablets had US sales of $450.4 million, as per IMS MAT September 2015.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.
